Influence of galectin-3 and soluble ST-2 on risk of death and heart failure hospitalization in patients after ST-elevation myocardial infarction treated with primary percutaneous coronary intervention

25 May 2019 (00:00 - 00:00)

Organised by:

Sign in to view the resources

About the speaker

Doctor Agata Tyminska

Medical University of Warsaw, Warsaw (Poland)

20 More presentations in this session

Presentation thumbnail

The ratio of fibroblast growth factor 23 to phosphorus as a predictor of cardiovascular death in heart failure patients with reduced ejection fraction.

Professor D. Gruson (Brussels, BE)

Abstract Slides

Presentation thumbnail

Soluble ST2/LVMI correlates with native T1 mapping value in 3T cardiac magnetic resonance in patients with dilated cardiomyopathy

Associate Professor Y. Park (Yangsan, KR)

Presentation thumbnail

Dynamics of the stimulating growth factor sST2 and interleukin 33 in acute myocardial infarction

Professor V. Larina (Moscow, RU)

Presentation thumbnail

BNP as the biomarker of diagnosis and prognosis in long-term mortality in a cohort with HFpEF and HFrEF in the south of Brazil

Doctor E. Pitthan (Porto Alegre, BR)

Presentation thumbnail

Association between severity of heart failure and chemerin level

Access the full session

Session thumbnail

Poster Session 2 - Chronic Heart Failure – Diagnostic Methods

The Event

Heart Failure 2019

25 May - 28 May 2019

You may be interested in

Congress Presentation

The role of a multimarker panel in the diagnosis and prognosis of patients with acute heart failure

Congress Presentation

Novel biomarkers reveal distinct biological phenotypes in heart failure with preserved vs reduced ejection fraction

Congress Presentation

Growth differentiation factor 15 and absorption loss as new biomarkers of heart failure decompensation

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources